HK1169999A1 - Human monoclonal antibodies to activin receptor-like kinase-1 (alk-1) -1 (alk-1) - Google Patents

Human monoclonal antibodies to activin receptor-like kinase-1 (alk-1) -1 (alk-1)

Info

Publication number
HK1169999A1
HK1169999A1 HK12110733.7A HK12110733A HK1169999A1 HK 1169999 A1 HK1169999 A1 HK 1169999A1 HK 12110733 A HK12110733 A HK 12110733A HK 1169999 A1 HK1169999 A1 HK 1169999A1
Authority
HK
Hong Kong
Prior art keywords
alk
kinase
monoclonal antibodies
human monoclonal
activin receptor
Prior art date
Application number
HK12110733.7A
Other languages
English (en)
Chinese (zh)
Inventor
Michael Aidan North
Jianying Wang
Grant Raymond Wickman
Jingchuan Zhang
Karin Kristina Amundson
Vahe Bedian
Shelley Sims Belouski
Dana Dan Hu-Lowe
Xin Jiang
Shannon Marie Karlicek
Sirid-Aimee Kellermann
James Arthur Thomson
Original Assignee
Amgen Fremont Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37906640&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1169999(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Fremont Inc filed Critical Amgen Fremont Inc
Publication of HK1169999A1 publication Critical patent/HK1169999A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
HK12110733.7A 2005-09-07 2012-10-26 Human monoclonal antibodies to activin receptor-like kinase-1 (alk-1) -1 (alk-1) HK1169999A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71529205P 2005-09-07 2005-09-07

Publications (1)

Publication Number Publication Date
HK1169999A1 true HK1169999A1 (en) 2013-02-15

Family

ID=37906640

Family Applications (2)

Application Number Title Priority Date Filing Date
HK12110733.7A HK1169999A1 (en) 2005-09-07 2012-10-26 Human monoclonal antibodies to activin receptor-like kinase-1 (alk-1) -1 (alk-1)
HK16107449.4A HK1219488A1 (zh) 2005-09-07 2016-06-27 針對類活化素受體激酶- 之人類單株抗體

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16107449.4A HK1219488A1 (zh) 2005-09-07 2016-06-27 針對類活化素受體激酶- 之人類單株抗體

Country Status (41)

Country Link
US (3) US7537762B2 (fr)
EP (4) EP1933871B1 (fr)
JP (3) JP5161777B2 (fr)
KR (3) KR101536487B1 (fr)
CN (2) CN107056943B (fr)
AP (2) AP2723A (fr)
AR (2) AR055152A1 (fr)
AU (1) AU2006297571B2 (fr)
BR (1) BRPI0615766A2 (fr)
CA (1) CA2621371C (fr)
CL (1) CL2010000096A1 (fr)
CR (3) CR9819A (fr)
CY (1) CY1120794T1 (fr)
DK (3) DK1933871T3 (fr)
DO (1) DOP2006000195A (fr)
EA (2) EA018453B1 (fr)
ES (3) ES2546069T3 (fr)
GE (1) GEP20125398B (fr)
GT (1) GT200600406A (fr)
HK (2) HK1169999A1 (fr)
HN (1) HN2006031275A (fr)
HU (2) HUE025608T2 (fr)
IL (2) IL189642A (fr)
LT (1) LT2960253T (fr)
MA (1) MA29843B1 (fr)
ME (1) ME00501B (fr)
MY (1) MY164457A (fr)
NL (1) NL1032452C2 (fr)
NO (1) NO20081718L (fr)
NZ (1) NZ566774A (fr)
PE (1) PE20080035A1 (fr)
PL (3) PL2447283T3 (fr)
PT (3) PT1933871E (fr)
RS (1) RS54393B1 (fr)
SI (3) SI2447283T1 (fr)
TN (1) TNSN08080A1 (fr)
TW (5) TWI370137B (fr)
UA (1) UA94060C2 (fr)
UY (1) UY29783A1 (fr)
WO (1) WO2007040912A2 (fr)
ZA (1) ZA200802971B (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
US7897581B2 (en) * 2005-02-24 2011-03-01 Massachusetts Eye & Ear Infirmary Methods and compounds for promoting vessel regression
UA94060C2 (ru) * 2005-09-07 2011-04-11 Эмджен Фримонт Инк. Моноклональное антитело, которое специфически связывает alk-1
WO2007090794A1 (fr) * 2006-02-10 2007-08-16 Nerviano Medical Sciences S.R.L. Combinaisons comprenant un inhibiteur de cdk et un anticorps anti-facteur de croissance ou un antimitotique
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
AU2012265564B2 (en) * 2006-09-08 2016-05-26 Amgen Inc Anti-activin A antibodies and uses thereof
US8642031B2 (en) 2006-11-02 2014-02-04 Acceleron Pharma, Inc. Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
US10059756B2 (en) 2006-11-02 2018-08-28 Acceleron Pharma Inc. Compositions comprising ALK1-ECD protein
AU2016247166B2 (en) * 2006-11-02 2018-09-27 Acceleron Pharma Inc. ALK1 receptor and ligand antagonists and uses thereof
EP2087001B1 (fr) 2006-11-02 2016-10-26 Acceleron Pharma, Inc. Récepteur alk1 et antagonistes de ligands et utilisations de ceux-ci
US7947646B2 (en) 2007-03-06 2011-05-24 Amgen Inc. Variant activin receptor polypeptides
PA8775101A1 (es) * 2007-04-02 2008-11-19 Pfizer Anticuerpos anti-ige
ITTV20070126A1 (it) 2007-07-16 2009-01-17 Luca Toncelli Procedimento ed apparecchiatura per la fabbricazione di lastre ad effet-to venato
CA2703099A1 (fr) * 2007-11-09 2009-05-14 Genentech, Inc. Compositions de kinase-1 similaires au recepteur d'activine et procedes d'utilisation
JP5769969B2 (ja) * 2007-11-12 2015-08-26 ユー３・ファーマ・ゲーエムベーハー Ａｘｌ抗体
RU2509085C2 (ru) * 2008-01-28 2014-03-10 Медиммун Лимитед Стабилизированные антитела против ангиопоэтина-2 и их применение
US7855564B2 (en) * 2008-02-14 2010-12-21 Delaware Capital Formation, Inc. Acoustic wave device physical parameter sensor
EP2281002A2 (fr) * 2008-04-25 2011-02-09 MorphoSys AG Anticorps anti-alk1 et leurs utilisations
TW201609138A (zh) * 2008-05-02 2016-03-16 艾西利羅製藥公司 調節血管新生與周圍細胞組成的方法與組合物
EP2291401A2 (fr) * 2008-05-15 2011-03-09 Acceleron Pharma, Inc. Antagonistes de bmp9 et bmp10, alk1 et autres ligands alk1, et leurs utilisations
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
PE20120206A1 (es) 2008-11-26 2012-03-09 Amgen Inc Variantes de polipeptidos receptores de activina iib
WO2010126169A1 (fr) * 2009-04-30 2010-11-04 協和発酵キリン株式会社 Composition pharmaceutique utilisée en prévention des maladies vasculaires et comprenant un inhibiteur d'alk1 comme principe actif
GB0915515D0 (en) * 2009-09-04 2009-10-07 Ucl Business Plc Treatment of vasculoproliferative conditions
US20110158987A1 (en) * 2009-12-29 2011-06-30 F. Hoffmann-Laroche Ag Novel antibody formulation
EP2585107B1 (fr) 2010-06-25 2018-10-24 Vaccibody AS Constructions de protéines homodimériques
SG11201403367YA (en) 2011-12-19 2014-07-30 Amgen Inc Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
EP2802355B1 (fr) 2012-01-09 2018-09-05 CovX Technologies Ireland Limited Anticorps mutants et leur conjugaison
WO2013155447A1 (fr) 2012-04-13 2013-10-17 Children's Medical Center Corporation Inhibiteurs tiki
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
MX2015009901A (es) * 2013-02-01 2016-04-06 Santa Maria Biotherapeutics Inc Administración de un compuesto de antiactivina a a un sujeto.
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
EP2787006B1 (fr) * 2013-04-02 2018-02-28 Miltenyi Biotec GmbH Anticorps anti-CD8 dont la liaison dépend de Ca2+
EP3712166A1 (fr) 2013-09-05 2020-09-23 Amgen Inc. Molécules contenant des fc et présentant des profils de glycoforme prévisibles, uniformes et reproductibles
WO2015175861A1 (fr) 2014-05-16 2015-11-19 Amgen Inc. Dosage pour la détection de populations de cellules th1 et th2
WO2016054023A1 (fr) * 2014-09-29 2016-04-07 Duke University Anticorps anti-vih-1 et utilisations de ceux-ci (adcc et ab bispécifiques)
GB201503438D0 (en) 2015-02-27 2015-04-15 Ucl Business Plc Antibodies
PE20180041A1 (es) 2015-06-05 2018-01-09 Novartis Ag Anticuerpos dirigidos a la proteina morfogenetica osea (bmp9) y metodos a partir de estos
KR101983013B1 (ko) * 2015-09-25 2019-05-28 동우 화인켐 주식회사 필름 터치 센서 및 그 제조 방법
JP2017077830A (ja) * 2015-10-21 2017-04-27 Ｋｙｂ株式会社 電動パワーステアリング装置
EP3413912A4 (fr) 2016-02-11 2019-09-25 The Johns Hopkins University Compositions et méthodes pour le ciblage de la signalisation de l'activine pour traiter le cancer
RU2615908C1 (ru) * 2016-05-16 2017-04-11 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ моделирования лимфогенного и гематогенного метастазирования мышиной меланомы В16 у белых нелинейных крыс
CN109689090B (zh) 2016-08-05 2023-12-26 免疫医疗有限责任公司 抗o2抗体及其用途
SG11201903063UA (en) 2016-10-19 2019-05-30 Medimmune Llc Anti-o1 antibodies and uses thereof
AU2018235928B2 (en) 2017-03-14 2023-09-21 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
MA52186A (fr) 2018-03-26 2021-02-17 Amgen Inc Glycoformes afucosylées totales d'anticorps produits en culture cellulaire
WO2021062372A1 (fr) 2019-09-26 2021-04-01 Amgen Inc. Procédés de production de compositions d'anticorps
EP4162257A1 (fr) 2020-06-04 2023-04-12 Amgen Inc. Évaluation de procédures de nettoyage d'un procédé de fabrication biothérapeutique
EP4229080A1 (fr) 2020-10-15 2023-08-23 Amgen Inc. Glycanes relatifs non appariés dans des procédés de production d'anticorps
EP4352094A1 (fr) 2021-06-07 2024-04-17 Amgen Inc. Utilisation de fucosidase pour contrôler le taux d'afucosylation de protéines glycosylées
CN115746142A (zh) * 2021-09-03 2023-03-07 开拓药业(广东)有限公司 抗alk-1/抗vegf双特异性抗体及其应用
WO2023059607A1 (fr) 2021-10-05 2023-04-13 Amgen Inc. Liaison de récepteur fc-gamma et teneur en glycane
WO2023215725A1 (fr) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions et méthodes pour l'immunothérapie cellulaire

Family Cites Families (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
WO1986005807A1 (fr) 1985-04-01 1986-10-09 Celltech Limited Lignee cellulaire de myelomes transformee et procede d'expression d'un gene codant un polypeptide eucaryotque employant cette lignee
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
JPH0341802A (ja) 1989-07-07 1991-02-22 Ngk Spark Plug Co Ltd 温度補償型マイクロ波ストリップラインフィルタ
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992003917A1 (fr) 1990-08-29 1992-03-19 Genpharm International Recombinaison homologue dans des cellules de mammiferes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
DE69233697T2 (de) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
DE69233750D1 (de) 1991-04-10 2009-01-02 Scripps Research Inst Bibliotheken heterodimerer Rezeptoren mittels Phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
DK0605522T3 (da) 1991-09-23 2000-01-17 Medical Res Council Fremgangsmåde til fremstilling af humaniserede antistoffer
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
US5770592A (en) 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
US5679666A (en) 1991-11-22 1997-10-21 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
ATE381614T1 (de) 1992-07-24 2008-01-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
WO1994011502A2 (fr) 1992-11-17 1994-05-26 Ludwig Institute For Cancer Research Kinases du type recepteurs activine, proteines possedant des domaines de kinase de serine/threonine et leur utilisation
US7592428B1 (en) 1992-11-17 2009-09-22 Ludwig Institute For Cancer Research Antibodies which bind specifically to activin receptor like kinases
US6692925B1 (en) 1992-11-17 2004-02-17 Ludwig Institute For Cancer Research Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use
ES2146648T3 (es) 1993-03-09 2000-08-16 Genzyme Corp Procedimiento de aislamiento de proteinas de la leche.
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5608082A (en) 1994-07-28 1997-03-04 Agouron Pharmaceuticals, Inc. Compounds useful as antiproliferative agents and GARFT inhibitors
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US6046037A (en) 1994-12-30 2000-04-04 Hiatt; Andrew C. Method for producing immunoglobulins containing protection proteins in plants and their use
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
EP0826034A4 (fr) 1995-04-21 2002-06-19 Cell Genesys Inc Creation d'importantes deletions d'adn genomique
ES2304786T3 (es) 1995-04-27 2008-10-16 Amgen Fremont Inc. Anticuerpos anti-il-8 humanos, derivados a partir de xenoratones inmunizados.
EP0823941A4 (fr) 1995-04-28 2001-09-19 Abgenix Inc Anticorps humains derives de xeno-souris immunisees
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
EP0845006A2 (fr) * 1995-08-14 1998-06-03 Creative Biomolecules, Inc. Liaison de la proteine oestrogene 1 (op-1) et de ses analogues avec le recepteur alk-1 de surface de cellule et ses analogues
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
US5663272A (en) 1995-12-22 1997-09-02 Bayer Corporation Allophanate-modified diphenylmethane diisocyanates and processes for their production and use
JP4464466B2 (ja) 1996-03-05 2010-05-19 アストラゼネカ・ユーケイ・リミテッド ４―アニリノキナゾリン誘導体
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
US6180651B1 (en) 1996-04-04 2001-01-30 Bristol-Myers Squibb Diarylmethylidenefuran derivatives, processes for their preparation and their uses in therapeutics
ES2311571T3 (es) 1996-04-12 2009-02-16 G.D. Searle Llc Derivados de bencenosulfonamida sustituidos como profarmacos de inhibidores de cox-2.
DE19616523A1 (de) * 1996-04-25 1997-11-06 Basf Ag Polymerisationskatalysatoren mit beta-Diketiminat-Liganden
JPH11512750A (ja) 1996-06-27 1999-11-02 ファイザー インク． ２―（２―オキソ―エチリデン）―イミダゾリジン―４―オンの誘導体およびファルネシル蛋白質トランスフェラーゼ阻害物質としてのそれらの使用法
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
ES2186908T3 (es) 1996-07-13 2003-05-16 Glaxo Group Ltd Compuestos heterociciclos condensados como inhibidores de pproteina-tirosina-quinasas.
TR199900048T2 (xx) 1996-07-13 1999-04-21 Glaxo Group Limited Protein tirozin kinaz inhibit�rleri olarak bisiklik heteroaromatik bile�ikler
CA2260016C (fr) 1996-07-18 2004-03-09 Merck Frosst Canada Inc. Pyridines substituees en tant qu'inhibiteurs selectifs de la cyclo-oxygenase-2
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
DK1500329T3 (da) 1996-12-03 2012-07-09 Amgen Fremont Inc Humane antistoffer, der specifikt binder TNF-alfa
US6034256A (en) 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
CA2289102A1 (fr) 1997-05-07 1998-11-12 Sugen, Inc. Derives de 2-indolinone utilises en tant que modulateurs de l'activite de la proteine kinase
EP1724282B1 (fr) 1997-05-21 2013-05-15 Merck Patent GmbH Procédé de production de protéines non-immunogènes
JP2002501532A (ja) 1997-05-30 2002-01-15 メルク エンド カンパニー インコーポレーテッド 新規血管形成阻害薬
ATE368665T1 (de) 1997-08-22 2007-08-15 Astrazeneca Ab Oxindolylchinazolinderivate als angiogenesehemmer
CO4960662A1 (es) 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
EP1017682A4 (fr) 1997-09-26 2000-11-08 Merck & Co Inc Nouveaux inhibiteurs de l'angiogenese
CN1280580A (zh) 1997-11-11 2001-01-17 辉瑞产品公司 用作抗癌药的噻吩并嘧啶和噻吩并吡啶衍生物
JPH11236333A (ja) 1997-12-30 1999-08-31 Pfizer Prod Inc 抗ガン剤として有用なイミダゾリン−４−オン誘導体
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
JP2002505097A (ja) 1998-03-03 2002-02-19 アブジェニックス インク． 治療薬としてのｃｄ１４７結合分子
AU3092899A (en) * 1998-03-13 1999-09-27 Ludwig Institute For Cancer Research Alk-1 responds to tgf-beta and signals through smad-1 and smad-5
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
HUP0103617A2 (hu) 1998-05-29 2002-02-28 Sugen, Inc. Protein kinázt gátló, pirrolilcsoporttal helyettesített 2-indolszármazékok, e vegyületeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
EP1105427A2 (fr) 1998-08-17 2001-06-13 Abgenix, Inc. Production de molecules modifiees avec demi-vie serique prolongee
JP3495706B2 (ja) 1998-08-27 2004-02-09 ファイザー・プロダクツ・インク 抗癌薬として有用なアルキニル置換キノリン−２−オン誘導体
WO2000012498A1 (fr) 1998-08-27 2000-03-09 Pfizer Products Inc. Derives de quinolin-2-one utiles en tant qu'agents anticancereux
EP1006113A1 (fr) 1998-12-02 2000-06-07 Pfizer Products Inc. Dérivés de 2-(2-oxo-éthylidène)-imidazolidin-4-one et leur utilisation pour inhiber la croissance anormale des cellules
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
KR100856446B1 (ko) 1998-12-23 2008-09-04 화이자 인크. Ｃｔｌａ－４에 대한 인간 단일클론 항체
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
EA200100766A1 (ru) 1999-02-11 2002-02-28 Пфайзер Продактс Инк. Хинолин-2-он замещенные гетероарильные производные, используемые в качестве противоопухолевых агентов
US5998206A (en) * 1999-02-23 1999-12-07 Isis Pharmaceuticals Inc. Antisense inhibiton of human G-alpha-12 expression
US6586447B1 (en) 1999-04-01 2003-07-01 Pfizer Inc 3,3-disubstituted-oxindole derivatives useful as anticancer agents
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
CN1184027C (zh) 1999-11-05 2005-01-12 株式会社阿玛达 压弯机
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
PT1106612E (pt) 1999-11-30 2004-06-30 Pfizer Prod Inc Derivados de quinolina uteis para inibir a farnesil-proteina-transferase
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
NZ519546A (en) * 1999-12-15 2005-07-29 Res Dev Foundation Betaglycan as an inhibin receptor and uses thereof
CA2399358C (fr) 2000-02-15 2006-03-21 Sugen, Inc. Inhibiteurs de la proteine kinase 2-indolinone a substitution pyrrole
US6584504B1 (en) 2000-05-26 2003-06-24 Networks Associates Technology, Inc. Method and apparatus for monitoring internet traffic on an internet web page
CA2413424C (fr) 2000-06-22 2007-10-02 Pfizer Products Inc. Derives bicycliques substitues destines au traitement de la croissance cellulaire anormale
CA2420192A1 (fr) 2000-09-20 2002-03-28 Human Genome Sciences, Inc. 21 proteines humaines secretees
AR032028A1 (es) 2001-01-05 2003-10-22 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
EP2009027B1 (fr) * 2001-04-27 2014-05-21 Kyowa Hakko Kirin Co., Ltd. Anticorps monoclonal anti-CD40
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
CA2467738A1 (fr) * 2001-12-03 2003-06-12 Abgenix, Inc. Anticorps contre l'antigene tumoral de l'anhydrase carbonique ix (ca ix)
EP1467756A4 (fr) * 2001-12-28 2007-03-21 Abgenix Inc Procedes d'utilisation d'anticorps anti-muc18
PA8580301A1 (es) 2002-08-28 2005-05-24 Pfizer Prod Inc Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
AU2003298816C1 (en) * 2002-12-02 2010-12-16 Amgen Fremont, Inc. Antibodies directed to Tumor Necrosis Factor and uses thereof
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
US7888333B2 (en) 2005-02-04 2011-02-15 Cp Kelco U.S., Inc. Targeted gene deletions for polysaccharide slime formers
UA94060C2 (ru) * 2005-09-07 2011-04-11 Эмджен Фримонт Инк. Моноклональное антитело, которое специфически связывает alk-1
JP6943759B2 (ja) 2017-12-28 2021-10-06 株式会社東海理化電機製作所 シフト装置

Also Published As

Publication number Publication date
MY164457A (en) 2017-12-15
EP1933871A4 (fr) 2009-10-28
ES2546069T3 (es) 2015-09-18
CN107056943A (zh) 2017-08-18
US7537762B2 (en) 2009-05-26
TWI569807B (zh) 2017-02-11
DOP2006000195A (es) 2017-08-15
IL189642A0 (en) 2008-06-05
JP5947840B2 (ja) 2016-07-06
EP2447283B1 (fr) 2015-07-15
CA2621371A1 (fr) 2007-04-12
TWI370137B (en) 2012-08-11
EP1933871A2 (fr) 2008-06-25
CN101517068B (zh) 2017-02-08
SI2447283T1 (sl) 2015-12-31
CR20130351A (es) 2013-08-13
AP2008004388A0 (en) 2008-04-30
CL2010000096A1 (es) 2010-06-25
TW201431883A (zh) 2014-08-16
IL218429A0 (en) 2012-04-30
UY29783A1 (es) 2007-04-30
NZ566774A (en) 2011-11-25
HK1219488A1 (zh) 2017-04-07
AU2006297571A2 (en) 2008-05-01
JP2009506791A (ja) 2009-02-19
CY1120794T1 (el) 2019-12-11
MA29843B1 (fr) 2008-10-03
PL2447283T3 (pl) 2015-12-31
JP5833978B2 (ja) 2015-12-16
TW201511773A (zh) 2015-04-01
EP3381945A1 (fr) 2018-10-03
DK1933871T3 (da) 2013-07-08
KR101536487B1 (ko) 2015-07-13
JP2014218514A (ja) 2014-11-20
JP2012228251A (ja) 2012-11-22
AP2013006963A0 (en) 2013-07-31
AR107003A2 (es) 2018-03-07
US20120052074A1 (en) 2012-03-01
PT2447283E (pt) 2015-10-08
KR20080045715A (ko) 2008-05-23
US8080646B2 (en) 2011-12-20
GT200600406A (es) 2007-07-13
HN2006031275A (es) 2010-10-29
PL2960253T3 (pl) 2018-11-30
PE20080035A1 (es) 2008-01-30
TWI541253B (zh) 2016-07-11
KR20130042648A (ko) 2013-04-26
AP2723A (en) 2013-08-31
US20070065444A1 (en) 2007-03-22
PT2960253T (pt) 2018-07-31
TW201311728A (zh) 2013-03-16
TWI453218B (zh) 2014-09-21
HUE038941T2 (hu) 2018-12-28
TNSN08080A1 (en) 2009-07-14
CN101517068A (zh) 2009-08-26
CR9819A (es) 2008-12-03
HUE025608T2 (en) 2016-03-29
CR20140239A (es) 2014-06-13
AU2006297571B2 (en) 2012-03-15
ME00501B (me) 2011-10-10
NO20081718L (no) 2008-06-03
EP2960253B1 (fr) 2018-06-06
EP3381945B1 (fr) 2020-08-19
DK2960253T3 (en) 2018-08-13
NL1032452C2 (nl) 2008-01-18
IL189642A (en) 2013-06-27
EP2447283A3 (fr) 2012-06-20
EP2447283A2 (fr) 2012-05-02
EP2960253A1 (fr) 2015-12-30
TW200801043A (en) 2008-01-01
AR055152A1 (es) 2007-08-08
ZA200802971B (en) 2009-10-28
TWI389919B (zh) 2013-03-21
KR101390127B1 (ko) 2014-05-13
JP5161777B2 (ja) 2013-03-13
DK2447283T3 (en) 2015-08-31
WO2007040912A3 (fr) 2009-04-30
UA94060C2 (ru) 2011-04-11
EA201300320A1 (ru) 2014-02-28
EA018453B1 (ru) 2013-08-30
EA200800759A1 (ru) 2008-08-29
ES2681656T3 (es) 2018-09-14
LT2960253T (lt) 2018-10-10
EP1933871B1 (fr) 2013-04-24
KR101536506B1 (ko) 2015-07-14
GEP20125398B (en) 2012-02-27
PL1933871T3 (pl) 2013-09-30
CA2621371C (fr) 2018-05-15
CN107056943B (zh) 2021-06-08
SI1933871T1 (sl) 2013-10-30
US20100197005A1 (en) 2010-08-05
ES2421146T3 (es) 2013-08-29
NL1032452A1 (nl) 2007-03-08
WO2007040912A2 (fr) 2007-04-12
RS54393B1 (en) 2016-04-28
AU2006297571A1 (en) 2007-04-12
PT1933871E (pt) 2013-07-17
SI2960253T1 (sl) 2018-10-30
BRPI0615766A2 (pt) 2009-06-16
US9221915B2 (en) 2015-12-29
KR20140004261A (ko) 2014-01-10
TW201030017A (en) 2010-08-16
RS20080103A (en) 2009-07-15

Similar Documents

Publication Publication Date Title
HK1169999A1 (en) Human monoclonal antibodies to activin receptor-like kinase-1 (alk-1) -1 (alk-1)
IL189788A0 (en) Human monoclonal antibodies to cd70
IL179672A0 (en) Anti-cd3 antibodies
IL177602A0 (en) Uses of anti-ctla-4 antibodies
IL191340A (en) Monoclonal antibodies against e8o
IL180852A0 (en) Anti-cd154 antibodies
IL231169A0 (en) Human monoclonal antibodies to fucosil - 1gm and methods of using antibodies against fucosil - 1gm
IL216381A0 (en) Antagonistic human light-specific human monoclonal antibodies
ZA200802051B (en) Anti-CD3 antibody formulations
IL181549A0 (en) Preparation of olmesartan medoxomil
ZA200802641B (en) Human monoclonal antibodies to CD70
ZA200901165B (en) Antagonistic human light-specific human monoclonal antibodies
ZA200804254B (en) Human monoclonal antibodies to O8E
PL382401A1 (pl) Przeciwciała anty-CD154
SI1951759T1 (sl) Protitelesa anti-EGFR

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230904